IMMUNOGEN INC License Agreements
14 Contracts & Agreements
- License and Option Agreement dated as of February 28, 2023 by and between ImmunoGen, Inc. and Vertex Pharmaceuticals Incorporated (Filed With SEC on April 28, 2023)
- License Agreement dated as of February 14, 2022 by and between the Registrant and Eli Lilly and Company (Filed With SEC on May 6, 2022)
- Development and License Agreement with Biogen Idec., Inc. dated October 1, 2006 (Filed With SEC on February 28, 2022)
- Development and License Agreement, dated as of October 20, 2008, by and between the Company and Bayer HealthCare AG (Filed With SEC on May 9, 2018)
- THIRD AMENDMENT TO LICENSE AGREEMENT FOR ANTI-HER2 ANTIBODIES (Filed With SEC on January 30, 2013)
- DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on May 10, 2012)
- OPTION AND LICENSE AGREEMENT (Filed With SEC on October 31, 2011)
- LICENSE AGREEMENT (Filed With SEC on October 31, 2011)
- AMENDMENT TO LICENSE AGREEMENTS (Filed With SEC on May 7, 2009)
- AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on September 2, 2008)
- LICENSE AGREEMENT (Filed With SEC on May 9, 2007)
- LICENSE AGREEMENT (Filed With SEC on May 9, 2007)
- Amendment to License Agreement for Anti-HER2 Antibodies (Filed With SEC on August 28, 2006)
- Development and License Agreement (Filed With SEC on February 14, 2002)
